Irodalom:
Sherman, K., Fleischer R., Laessing K., Murry J., Tauber W., Birnkrant, D: Development of novel
agents for the treatment of chronic hepatitis C infection: Summry of the FDA antiviral products advisory committee
recommendations. Hepatology 46: 2014-2020, 2007.
Pappas, S.Ch.: Good science behind hepatitis C virus antiviral drug development: Necessary but not
sufficient. Hepatology 46: 1317-1319, 2007.
Mc Hutchinson J.J., Bacon B.R., Gordon,S.C. et al: A phase 1B, randomized, double-blind, dose escalation
trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46:DOT 10.1002/hep.21773, 2007.
Szabó E., Lotz G., Páska Cs., Kiss A., Schaff Zs: Viral hepatitis: New data on hepatitis C infection. POR
9:215-221 2003.
Bartenschlager, R.: New insights into the HCV replication cycle: Lessons learned from novel culture
systems. Global Antiviral Journal, 3: Suppl.2. (HepDart 2007) abstr04, p8. 2007.
Pietropaolo K., Belanger B., Zhou X., Fielman B., Olek E., Leone J., Mayers D: Development of an
HCV nucleoside polymerase inhibitor. HepDart 2007 Satellite Symposium. Toward Curative Therapes for Hepatitis
C. P11.
Stoltz J.H., Stern,J.O: A 28-day mechanistic safety study in rhesus monkeys on hepatitis C virus protease
inhibitor BILN 2061: Lessons learned. HepDart 2007 Satellite Symposium. Toward Curative Therapies
for Hepatitis C. P7.
Bavisotto, L., Wang C., Jacobson.I. et al: Antiviral, pharmacokinetic and safety data for GS-9190, a
non-nucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects.
HepDart 2007 Satellite Symposium. P9-10.
McNair, L.: Specifically targeted therapies for HCV (STAT-C): An update on Telaprevir. HepDart 2007
Satellite Symposium, p13.
Olsen,D.B., Handt,L., Koeplinger,K., Ludmerer S. Et al: A combination of direct antiviral compounds
can achive sustained viral response in hepatitis C virus-infected chimpanzees. Global Antiviral Journal 3: Suppl2,
(HepDart 2007) abstr 60, p65, 2007.
A máj 365
Nelson,D., Pockros, P.J., Godofsky, E., Rodriguez-Torres,M. Et al: R1626 demonstrates synergistic
antiviral effect in combination with Peginterferon alfa-2a (40KD), with or without Ribavirin, and high barrier
resistance development. Global Antiviral Journal 3: Suppl2, (HepDart 2007) abstr 62, p66, 2007.
Pileri P., Uematsi Y., Compagnoli S., Galli G. Et al: Binding of hepatitis C virus to CD81. Science
282:938-941, 1998.
Scarselli E., Ansuini H., Cerino R., Roccasecca R.M. et al: The human scavenger receptor class B type
I is a novel candidate receptor for hepatitis C virus. EMBO J. 21:5017-5025, 2002.
Evans, M.J., von Hahn,T., Tscherne D.M., Syder A.J. et al: Caludin-1 is a hepatitis C virus co-receptor
required for a late step in entry. Nature 446:801-805, 2007.
Crabbé R.: The role of Cyclophilins and Cyclophilin inhibitors in the replication of HCV.
Luscombe, C.A., Huang, Z., Murray M., Miller M., Ewart G: A novel anti-viral compound BIT225,
inhibits Bovine Diarrhea Virus (BVDV) in vitro, and has synergistic antiviral acitivity in combination with
recombinant interferon alpha-2b (rIFNa-2b) and Ribavirin.
Hausman D.F., Freeman J.A., Souza S.M., Nestorov J.A., Zhang T: A phase 1, randomized, blinded,
placebo-controlled, single-dose, dose-escalation study of PEG-Interferon lambda (PEG-rIL-29) in healthy subjects.
Global Antiviral Journal 3: Suppl2, (HepDart 2007) abstr 67, p71, 2007.
Fujiwara K., Kaneko S., Kakumu S., Sata M. Et al: Double filtration plasmapheresis and interferon
combination therapy for chronic hepatitis C patients with genotye 1 and high viral load. Hepatology Res
37:701-710, 2007.
